Introduction: Previous research has
Methods: Preferences for dosing of oral antihyperglycemic drugs (OAD) were evaluated by surveying patients with T2DM in the United States (US). Survey participants were adult US patients with T2DM who were taking no or only 1 OAD and no injectable therapies. Each patient completed a web-enabled discrete-choice experiment (DCE) including a series of 8 pairs of hypothetical OAD profiles. Each profile was defined by reductions in average glucose, dosing schedule (e.g., once-weekly, once-daily, or twice-daily dosing), chance of mild-tomoderate gastrointestinal side effects, frequency of hypoglycemia, weight change, incremental risk of congestive heart failure, and cost. Each participant also answered a direct question about dosing preference. Random-parameters logit was used to analyze the DCE data. Prespecified subgroups were analyzed.
Results: Of 2,262 patients invited to participate, 923 were included in the analysis (mean age 63 years, 45% male, 79% white).
Reducing dosing frequency was statistically significantly important to patients; however, it was relatively less important than medication cost or clinical outcomes. On average, patients preferred once-weekly to once-daily dosing.
Patients not currently taking an OAD had a
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INTRODUCTION
Previous research has demonstrated a correlation between dosing burden and medication nonadherence [1] [2] [3] . In type 2 diabetes mellitus (T2DM), therapies including combinations of oral antihyperglycemic drugs (OADs) can result in high nonadherence [4] .
However, poor adherence to oral antidiabetes therapies is not limited to combination therapies and is common among patients just starting monotherapy [5] . A number of studies have demonstrated that patients with T2DM are willing to forgo the benefits of treatment to reduce treatment burden [6] and have identified a relationship between patients' preferences and likely medication adherence [7, 8] . Other studies have suggested that less frequent dosing may result in greater patient adherence, improved treatment outcomes, and reduced health care costs [9] [10] [11] [12] . Discrete-choice experiments (DCEs), also known as choice-format conjoint analysis studies, increasingly have been used to determine the tradeoffs that patients are willing to make among features of medical interventions [13] [14] [15] . This method is based on the premise that medical interventions are composed of a set of attributes or outcomes, that the attractiveness of a particular intervention to an individual is a function of these attributes, and that choices among alternatives reveal patients' relative preferences for these attributes [16] . A recent study demonstrated that patients with T2DM have preferences for reducing the dosing burden of combination OAD therapy and that patients with lower current overall medication burden were more likely to indicate that decreases in dosing burden would result in an improvement in their expected medication adherence [7] . The objective of the current study was to elicit preferences for alternative dosing regimens for OAD therapies among patients with T2DM and to quantify differences in dosing preferences among patients with different characteristics.
METHODS

Study Sample
Patients were recruited from a probability- 
Survey Instrument
The online DCE survey was adapted from a survey used in a previous study [7] and developed using good research practices [13] .
The survey included a series of eight choice questions; each question presented a pair of hypothetical, but realistic, OAD medication profiles ( Fig. 1 and in consultation with clinical experts [7] . The ranges of the attribute levels were chosen to encompass the range of outcome levels described in the clinical trials literature, as well as the range over which patients were willing to accept tradeoffs [7] . The dosing attribute included three levels (one pill once daily, two pills once daily, and one pill twice daily) based on available starting doses for 
Statistical Analysis
The medication choice data were analyzed using a random-parameters logit model with NLOGIT 4.0 (Econometric Software, Inc, Plainview, NY, USA). Random-parameters logit controls for unobserved preference heterogeneity among respondents by estimating a distribution for each preference parameter [19, 20] . The resulting parameter estimates can be interpreted as relative preference weights. The difference between the relative preference weights on the best and worst levels of the attribute is the relative importance of each attribute over the range of levels included in the survey.
The proportion of patients who preferred once-weekly dosing over daily-dosing alternatives was calculated for the overall sample and for each of the prespecified subgroups. For each pair of subgroups, P values (a = 0.05) were calculated using a Chi-squared test of the difference between the proportion of patients who preferred once-weekly dosing and the proportion of patients who preferred oncedaily dosing.
RESULTS
Study Sample
A total of 2,262 email invitations were sent to panel members. Of the 940 patients who responded and consented to participate, 13 patients were excluded from the analysis because they had no variation in their responses (i.e., they chose either Medicine A or Medicine B for every choice question). This response pattern indicated that the patient was inattentive to the choice questions. An additional 4 patients did not complete any of the choice questions. The final sample included 923 respondents with a mean age of 63 years; 45% of the respondents were male, and 79%
were white. Most respondents (79%) reported that they were currently using an OAD. Table 1 summarizes the characteristics of the respondents.
Relative Importance Scores
Relative importance scores are presented in was the most important treatment attribute and was statistically significantly more important than efficacy, side effects, and dosing.
Reduction in AG was statistically significantly more important than dosing and the remaining clinical outcomes. Hypoglycemia, chance of mild-to-moderate gastrointestinal side effects, weight change within the first 6 months of starting treatment, and incremental increase in the risk of CHF were of approximately equal importance. Once-weekly dosing was preferred to one pill once daily. One pill once daily was preferred to one pill twice daily, which, in turn, was preferred to two pills once daily. The difference in preference weights between the most preferred dosing option (one pill once 
Dosing Preferences
Patients' dosing preferences are presented in Fig. 4 . Among all patients, 67% preferred weekly dosing to any of the daily-dosing schedules. Among patients not currently taking any OAD, 75% preferred once-weekly dosing to dailydosing options. This proportion was statistically significantly greater (P = 0.012) than the 65% of patients currently using an OAD who preferred once-weekly dosing over daily dosing. Among younger patients (aged\45 years), 78% preferred once-weekly dosing to daily dosing; in contrast, 66% of patients aged 45-64 years (P = 0.065 vs. the younger age group) and 66% of patients aged 65 years or older (P = 0.074 vs. the younger age group) preferred once-weekly dosing to daily dosing, although these findings were not statistically significant. Similar proportions of patients whose T2DM was diagnosed within the previous 3 years and patients whose T2DM was diagnosed more than 3 years ago preferred once-weekly dosing to daily dosing: 66% of patients with a more recent diagnosis preferred once-weekly dosing, and 67% of patients with a diagnosis more than 3 years ago preferred onceweekly dosing.
DISCUSSION
Dosing burden has been found to influence patients' expectations about medication adherence in T2DM [7] and in other chronic diseases [21] . In this study, we administered a survey among patients with T2DM to elicit their preferences among treatment attributes (including efficacy, tolerability, daily dosing, and cost) to quantify the relative importance of reducing OAD dosing burden. Dosing preferences were elicited using both a DCE and a direct question.
Many studies have examined patients' preferences for dosing; however, the results of these studies are mixed. Some studies find that patients have statistically significant preferences for less frequent dosing while others do not. For example, Hauber et al. [7] found that patients with T2DM had statistically significant preferences for reducing daily-dosing frequency, especially among patients with lower current dosing burdens. Likewise, de Bekker-Grob et al. [22] found that reducing the frequency of dosing for osteoporosis prophylaxis was approximately equally important as reducing the 10-year risk of osteoporosis by 10 percentage points among women in the Netherlands. In contrast, Lancsar et al. [23] and King et al. [24] found that preferences for reducing the frequency of daily dosing of asthma medications were not statistically significant predictors of treatment choice among asthma patients in Australia.
Although dosing was less important to patients with T2DM than clinical outcomes and cost in this study, patients had strong and statistically significant preferences for changes in dosing. In addition, patients had strong and statistically significant preferences for onceweekly dosing relative to alternative dailydosing regimens. Patients not currently taking an OAD had stronger preferences for weekly dosing than did patients who were currently taking an OAD. A higher proportion of patients aged 44 years and younger preferred onceweekly dosing to once-daily dosing when compared with patients aged 45 years and older, although this difference was not statistically significant. The lack of statistical significance for the difference in preferences for once-weekly dosing (12 percentage points) between younger and older patients may be due to the small sample size in the lower age group. Time since diagnosis did not have a Fig. 3 Relative importance scores for attributes in the discrete-choice experiment. The largest relative importance score was set equal to 10 and all other relative importance scores were calculated relative to the largest relative importance score measureable impact on dosing preferences among the patients in this study.
As all stated-preference studies, this study is subject to limitations. The results of this study should be interpreted with these limitations in mind. First, the survey asked patients to evaluate hypothetical scenarios. Although this practice is commonly used for eliciting patient preferences, the choices indicated by patients do not have the same impact as actual choices.
In addition, none of the patients in this study had prior experience with weekly or less frequent dosing of OADs. Therefore, we cannot make any definitive statements about the effect of this type of experience on dosing preferences. Second, our study implicitly assumes that all clinical, convenience, and economic attributes of treatment that are not included in the DCE are held constant across the alternatives presented in the choice questions. In theory, adding these attributes to the DCE should not change our results; however, it is unknown whether including additional attributes in or deleting attributes from this particular study would yield different results. Finally, diagnosis of T2DM was selfreported, and the final sample may not be representative of the population of patients with T2DM in the US.
Patients in this study were asked to indicate which of four possible OAD dosing options they preferred. Overall, and in each subgroup evaluated in this study, patients preferred once-weekly dosing to daily dosing. These preferences were stronger for younger patients and patients not currently taking an OAD. 
